Exact Mass: 340.0308

Exact Mass Matches: 340.0308

Found 26 metabolites which its exact mass value is equals to given mass value 340.0308, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   

2-(6-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone

2-(6-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone

C17H13BrN2O (340.0211)


   

Methyl (2R)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoate

Methyl (2R)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoate

C16H14Cl2O4 (340.0269)


   

1,13-Dibromotridecane

1,13-Dibromotridecane

C13H26Br2 (340.0401)


   

2-ETHOXY-5-(PYRIDINE-2-CABOXAMIDO) BENZENE-1-SULFONYL CHLORIDE

2-ETHOXY-5-(PYRIDINE-2-CABOXAMIDO) BENZENE-1-SULFONYL CHLORIDE

C14H13ClN2O4S (340.0285)


   

2-(7-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone

2-(7-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone

C17H13BrN2O (340.0211)


   

Minodronic acid monohydrate

Minodronic acid monohydrate

C9H14N2O8P2 (340.0225)


D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates

   

Fenoprofen CalciuM Salt Dihydrate

Fenoprofen CalciuM Salt Dihydrate

C15H14O3.1/2Ca.H2O (340.03)


   

Methyl (2S)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoate

Methyl (2S)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoate

C16H14Cl2O4 (340.0269)


   

BARIUM TETRAHYDROFURFURYLOXIDE

BARIUM TETRAHYDROFURFURYLOXIDE

C10H18BaO4 (340.0257)


   

Defosfamida [INN-Spanish]

Defosfamida [INN-Spanish]

C9H20Cl3N2O3P (340.0277)


   

2-ETHOXY-5-[(PYRIDINE-3-CARBONYL)-AMINO]-BENZENESULFONYL CHLORIDE

2-ETHOXY-5-[(PYRIDINE-3-CARBONYL)-AMINO]-BENZENESULFONYL CHLORIDE

C14H13ClN2O4S (340.0285)


   

9,10-Dimethoxyanthracene-2-Sulfonic Acid Sodium Salt

9,10-Dimethoxyanthracene-2-Sulfonic Acid Sodium Salt

C16H13NaO5S (340.0381)


   

S-(Trifluoromethyl)dibenzothiophenium tetrafluoroborate

S-(Trifluoromethyl)dibenzothiophenium tetrafluoroborate

C13H8BF7S (340.0328)


   
   

2-BENZYLAMINO-4-CHLORO-5-SULFAMOYLBENZOIC ACID

2-BENZYLAMINO-4-CHLORO-5-SULFAMOYLBENZOIC ACID

C14H13ClN2O4S (340.0285)


   

6-Hydroxyuridine-5-phosphate

6-Hydroxyuridine-5-phosphate

C9H13N2O10P (340.0308)


   

7-Chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone

7-Chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone

C15H8ClF3N2O2 (340.0226)


   

[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

C9H13N2O10P (340.0308)


   

1-(5-Phospho-beta-d-ribofuranosyl)barbituric acid

1-(5-Phospho-beta-d-ribofuranosyl)barbituric acid

C9H13N2O10P (340.0308)


   

[(2S,3R,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

[(2S,3R,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

C9H13N2O10P (340.0308)


   

(3S,4S,5S,6S)-6-fluoro-4-hydroxy-3-[hydroxy(methyl)phosphoryl]oxy-5-(2-hydroxyprop-2-enoyloxy)cyclohexene-1-carboxylic acid

(3S,4S,5S,6S)-6-fluoro-4-hydroxy-3-[hydroxy(methyl)phosphoryl]oxy-5-(2-hydroxyprop-2-enoyloxy)cyclohexene-1-carboxylic acid

C11H14FO9P (340.0359)


   

(3S,4S,5S,6R)-6-fluoro-4-hydroxy-3-[hydroxy(methyl)phosphoryl]oxy-5-(2-hydroxyprop-2-enoyloxy)cyclohexene-1-carboxylic acid

(3S,4S,5S,6R)-6-fluoro-4-hydroxy-3-[hydroxy(methyl)phosphoryl]oxy-5-(2-hydroxyprop-2-enoyloxy)cyclohexene-1-carboxylic acid

C11H14FO9P (340.0359)


   

[(2S,3R,4R,5R)-3,4-dihydroxy-5-(2,4,6-trioxo-1,3-diazinan-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

[(2S,3R,4R,5R)-3,4-dihydroxy-5-(2,4,6-trioxo-1,3-diazinan-1-yl)oxolan-2-yl]methyl dihydrogen phosphate

C9H13N2O10P (340.0308)


   

5,6-Dihydroxy-2-deoxyuridine 5-monophosphate

5,6-Dihydroxy-2-deoxyuridine 5-monophosphate

C9H13N2O10P (340.0308)


A pyrimidine 2-deoxyribonucleoside 5-monophosphate having 5,6-dihydroxyuracil as the nucleobase.

   

SBI-115

SBI-115

C14H13ClN2O4S (340.0285)


SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5[1].